Enanta Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $17,159 | $18,615 | $15,125 | $18,314 |
Gross Profit | 15,950 | 18,615 | 15,125 | 18,314 |
EBITDA | -8,559 | -7,601 | -14,997 | -15,398 |
EBIT | -9,768 | -8,831 | -16,281 | -16,608 |
Net Income | -13,091 | -11,938 | -18,700 | -18,255 |
Net Change In Cash | 17,159 | 18,615 | 15,125 | 18,314 |
Free Cash Flow | -7,171 | -11,842 | -7,947 | 17,351 |
Cash | 34,928 | 37,437 | 32,298 | 44,812 |
Basic Shares | 21,380 | 21,380 | 21,380 | 21,322 |
Annual Financials
| Values in thousands | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
Revenue | $65,324 | $67,635 | $79,204 | $86,160 |
Gross Profit | 60,738 | 67,635 | 79,204 | 86,160 |
EBITDA | -70,779 | -104,512 | -123,476 | -119,215 |
EBIT | -75,868 | -106,848 | -125,847 | -122,188 |
Net Income | -81,889 | -116,045 | -133,816 | -121,755 |
Net Change In Cash | 65,324 | 67,635 | 79,204 | 86,160 |
Cost of Revenue | -9,852 | |||
Free Cash Flow | -32,168 | -96,712 | -112,212 | -86,907 |
Cash | 32,298 | 37,233 | 85,388 | 43,994 |
Basic Shares | 21,336 | 21,157 | 20,969 | 20,603 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.45 |
2025-12-31 | -$0.42 |
2025-09-30 | -$0.87 |
2025-06-30 | -$0.85 |